The latest from Faes Farma


November 4th, 2025

Faes Farma increases its revenue by more than 15% to €454 million


The company exceeds its revenue forecasts for the year as a whole thanks to the strong performance across all business areas The Pharma division posts double-digit growth (+13%) driven by strong performance […]



More info

September 2nd, 2025

Faes Farma completes the acquisition of SIFI and consolidates its international leadership in ophthalmology


The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]



More info

July 24th, 2025

Faes Farma increases revenue by 12.3% to €307.4 million


The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]



More info

All the news